India markets closed
  • BSE SENSEX

    52,586.84
    -66.23 (-0.13%)
     
  • Nifty 50

    15,763.05
    -15.40 (-0.10%)
     
  • USD/INR

    74.3370
    +0.0910 (+0.12%)
     
  • Dow

    34,935.47
    -149.03 (-0.42%)
     
  • Nasdaq

    14,672.68
    -105.59 (-0.71%)
     
  • BTC-INR

    3,060,053.25
    -14,167.50 (-0.46%)
     
  • CMC Crypto 200

    955.03
    +5.13 (+0.54%)
     
  • Hang Seng

    25,961.03
    -354.29 (-1.35%)
     
  • Nikkei

    27,283.59
    -498.83 (-1.80%)
     
  • EUR/INR

    88.3321
    +0.0474 (+0.05%)
     
  • GBP/INR

    103.4671
    -0.1908 (-0.18%)
     
  • AED/INR

    20.1960
    +0.0260 (+0.13%)
     
  • INR/JPY

    1.4721
    +0.0008 (+0.05%)
     
  • SGD/INR

    54.9030
    +0.0090 (+0.02%)
     

ADMA Biologics to Participate in the Raymond James Human Health Innovation Virtual Conference

·2-min read

RAMSEY, N.J. and BOCA RATON, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Human Health Innovation Virtual Conference on June 21, 2021 at 9:20 a.m. ET.

A webcast of the event will be available on the Company’s website at https://ir.admabiologics.com/events-webcasts and will be archived for 90 days following the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552| sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting